Rhythm Pharmaceuticals (RYTM) to Release Earnings on Tuesday

Rhythm Pharmaceuticals (NASDAQ:RYTM) will announce its earnings results after the market closes on Tuesday, November 5th. Analysts expect the company to announce earnings of ($0.80) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its earnings results on Tuesday, August 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.16. The firm had revenue of $29.08 million during the quarter, compared to analyst estimates of $28.79 million. Rhythm Pharmaceuticals had a negative net margin of 254.88% and a negative return on equity of 221.65%. Rhythm Pharmaceuticals’s revenue was up 51.3% on a year-over-year basis. During the same period in the previous year, the business posted ($0.82) EPS. On average, analysts expect Rhythm Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Rhythm Pharmaceuticals Stock Up 2.7 %

Rhythm Pharmaceuticals stock opened at $49.01 on Friday. The firm has a 50-day moving average price of $49.69 and a two-hundred day moving average price of $45.02. The firm has a market capitalization of $3.00 billion, a price-to-earnings ratio of -11.24 and a beta of 2.09. Rhythm Pharmaceuticals has a 52-week low of $23.26 and a 52-week high of $55.64.

Insider Activity

In other news, insider Pamela J. Cramer sold 3,200 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $50.01, for a total transaction of $160,032.00. Following the sale, the insider now owns 13,500 shares in the company, valued at $675,135. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Pamela J. Cramer sold 3,200 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $50.01, for a total transaction of $160,032.00. Following the sale, the insider now owns 13,500 shares in the company, valued at $675,135. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Pamela J. Cramer sold 49,006 shares of the business’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $45.15, for a total transaction of $2,212,620.90. Following the sale, the insider now owns 13,500 shares in the company, valued at $609,525. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 109,857 shares of company stock worth $5,325,446 over the last 90 days. 5.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $55.00 price target on shares of Rhythm Pharmaceuticals in a research note on Wednesday. JMP Securities assumed coverage on shares of Rhythm Pharmaceuticals in a research note on Tuesday, September 17th. They issued an “outperform” rating and a $64.00 price target for the company. Bank of America upped their price target on shares of Rhythm Pharmaceuticals from $48.00 to $52.00 and gave the stock a “neutral” rating in a research note on Monday, October 14th. Guggenheim assumed coverage on shares of Rhythm Pharmaceuticals in a research note on Monday, October 21st. They issued a “buy” rating and a $70.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $64.00 price target on shares of Rhythm Pharmaceuticals in a research note on Friday, October 25th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $60.33.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.